Tasigna Linked to Coronary Artery Disease
Researchers have linked the popular cancer treatment drug, Tasigna (generic name, nilotinib), manufactured by Novartis to irreversible atherosclerosis, coronary artery disease, and peripheral arterial disease (PAD), which can be deadly. This condition causes plaque build-up in a patient’s artery walls, causing them to harden and become thick and narrow. Thus, it lessens the ability for blood
Read More
Researchers Link Cancer Drug Tasigna to Atherosclerosis
Researchers continue to link the popular cancer treatment drug, Tasigna to atherosclerosis. However, the manufacturer of the drug, Novartis still continues to deny the connection. In fact, they won’t update the label to warn American consumers even though they warned Canadian ones. About Tasigna Manufacturer Novartis received FDA approval for Tasigna in 2007. Tasigna
Read More